Giuseppe Lombardi, Head of the Neuro-Oncology Unit at Veneto Oncology Institute IOV – IRCCS, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“New paper accepted in Neuro-Oncology!
Epigenetic evolution of IDH-wildtype glioblastomas
Main findings:
- The analysis shows that the DNA methylome is highly stable over time, including at tumor recurrence.
- Accordingly, the MGMT promoter methylation status rarely changes during disease progression.
Key data:
- ~93% of tumors retain the same MGMT status from diagnosis to recurrence
- Only ~7% show a change at progression
- Conversion to an unmethylated MGMT promoter is uncommon but associated with worse outcomes
Clinical implication:
In most patients, MGMT assessed at diagnosis can reliably be used also at recurrence, without the need for routine re-testing.
A sincere thank you to Prof. Pim French for the opportunity to contribute to this work and for his scientific leadership.
Thanks to all co-authors for the excellent collaboration.”
Title: Epigenetic evolution of IDHwt glioblastomas
Authors: Bo Deng , Rania Head , Kaspar Draaisma , Ann Hoeben , Slávka Lukacova , Giuseppe Lombardi , Sieger Leenstra , Monique Hanse , Ruth E M Fleischeuer , Colin Watts , Nicos Angelopoulos , Thierry Gorlia , Vincent Bours , Martin J Van Den Bent , Pierre A Robe , Youri Hoogstrate , Pim J French
Read the Full Article on Neuro-Oncology
More posts featuring Giuseppe Lombardi.
